Related Experiment Video
Updated: Jun 28, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
The appropriate role of cost-effectiveness in determining device coverage: a case study of drug-eluting stents
Brian Garriock Firth1, Liesl M Cooper, Steve Fearn
1Cordis Corporation, a Johnson and Johnson subsidiary in Warren, New Jersey, USA.
Abstract:
The use of incremental cost-effectiveness ratios based on quality-adjusted life-years (QALYs) as a critical determinant of what should be covered by a health system is a growing trend. This presents challenges when applied to rapidly evolving technologies. The case study here focuses on the example of drug-eluting stents and the four-year change in cost-effectiveness as determined by the U.K. National Institute for Health and Clinical Excellence (NICE). We contend that classic cost-effectiveness as a blunt instrument for determining what should be covered may lead to erroneous conclusions when a broader perspective and the impact on health outcomes and costs are considered.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Coronary Artery Disease V: Interprofessional Care